FDA Accepts Supplement Application for NULIBRY by Sentyln Therapies
The FDA has accepted the supplemental application NDA214018 for NULIBRY, an enzyme replacement therapy containing fosdenopterin hydrobromide, submitted by Sentyln Therapies.
Therapeutic Area
Therapeutic area intelligence for Enzyme Replacement Therapy with 4 indexed intelligence signals across regulatory, clinical, competitive, and market developments.
The FDA has accepted a supplemental NDA for NULIBRY, an enzyme replacement therapy for a rare disease.
No catalysts indexed for this entity yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.